Free Trial
NASDAQ:ADTX

Aditxt 5/15/2025 Earnings Report

Aditxt logo
$1.23 -0.02 (-1.92%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.22 -0.01 (-0.90%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aditxt EPS Results

Actual EPS
-$8.12
Consensus EPS
-$26,400.00
Beat/Miss
Beat by +$26,391.88
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$0.43 million
Beat/Miss
Missed by -$424.00 thousand
YoY Revenue Growth
N/A

Aditxt Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aditxt's next earnings date is estimated for Monday, August 18, 2025, based on past reporting schedules.

Conference Call Resources

Aditxt Earnings Headlines

Aditxt CEO Discusses Strategic Growth at Livestream Event
Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX), a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

View Aditxt Profile

More Earnings Resources from MarketBeat